Skip to Main Content

Latest articles

Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF)
Ryan P Coyle and others
Tenofovir alafenamide/emtricitabine-based antiretroviral tablets, co-encapsulated with an ingestible sensor, directly measured adherence during a 16-week pharmacokinetic study among persons with HIV. We propose tenofovir-diphosphate (≥1800 fmol/punches)/emtricitabine-triphosphate (≥2.5 pmol/punches) benchmarks in dried blood spots for ≥85% adherence to unboosted antiretroviral therapy.
Association between Causative Pathogen and Occurrence of Infection-Related Glomerulonephritis in Infective Endocarditis
Nabin K Shrestha and others
Among patients with pathologically-proven infective endocarditis, the association of pathogen with occurrence of infection-related glomerulonephritis (IRGN) was examined in 48 cases of IRGN and 192 propensity score-matched controls. Bartonella was very strongly associated with IRGN (OR 38.2, 95% C.I. 6.7–718.8, p-value ...
For Tuberculosis, Not “To Screen or Not to Screen?” but “Who?” and “How?”
Maha Reda Farhat and Karen Rita Jacobson
Active case finding leveraging new molecular diagnostics and chest X-rays with automated interpretation algorithms is increasingly being developed for high-risk populations to drive down tuberculosis incidence. We consider why such an approach did not deliver a decline in tuberculosis prevalence in Brazilian prison ...
Duration of Effective Tuberculosis Treatment, not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for Deisolation in Community Settings
Neela Goswami and Caitlin Reed
NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings
Maunank Shah and others

Editor's Choice

Which form of tenofovir should be used worldwide: TDF or TAF?
Andrew Hill
Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV
José Damas and others
In the Swiss HIV Cohort Study, replacing tenofovir alafenamide (TAF) with tenofovir disoproxil fumarate (TDF) resulted in a -1.84 kg weight decrease within one year. No substantial weight changes were noted after switching from TAF to dolutegravir/lamivudine or cabotegravir/rilpivirine.
Increased Pediatric Respiratory Syncytial Virus Case Counts Following the Emergence of Severe Acute Respiratory Syndrome Coronavirus 2 Can Be Attributed to Changes in Testing
Brittany A Petros and others
After the initial phase of the COVID-19 pandemic, hospitals reported an increase in RSV cases. We examined encounters at US pediatric hospitals and found that increased testing is likely driving the observed increase in case volume.
Effectiveness and safety of measures to prevent infections and other complications associated with peripheral intravenous catheters: A systematic review and meta-analysis
Andreea Dobrescu and others
Our systematic review emphasizes the pressing need for additional high-quality studies addressing preventive measures for reducing peripheral intravenous catheter-associated complications. The available evidence supports wearing gloves during insertion and adhering to defined removal schedules in adults, and chlorhexidine disinfection in neonates.
Clinical Predictors and Outcomes of Invasive Anal Cancer for People With Human Immunodeficiency Virus in an Inception Cohort
Edward R Cachay and others
People with human immunodeficiency virus with both cytological anal high-grade squamous intraepithelial lesion and nadir CD4 cell count ≤200/µL face 13-fold increased anal cancer risk compared with those lacking both. Anal cancer mortality (21%) occurred exclusively among stage IIIA patients.

Best of the IDSA Journals 2023

As we usher in the new year, the IDSA journals would like to thank all the excellent authors and peer reviewers that have contributed their expertise in 2023. The Editors-in-Chief of Clinical Infectious Diseases, The Journal of Infectious Diseases, and Open Forum Infectious Diseases have each selected 5 articles that represent significant contributions in their fields. We invite you to explore the sample of impressive research online.

Read the collection

CID Now Offers Review Pathway for Papers Rejected by High-Impact Journals

Clinical Infectious Diseases welcomes papers that have been peer reviewed by another medical journal and were not accepted for publication, where the authors believe they can address the essential concerns identified by previous reviewers. Under this new pathway, authors can revise the paper according to the review comments they previously received and then submit the paper to CID. This new pathway is intended to speed publication and minimize unnecessary re-review of papers that previously received thorough and detailed review elsewhere.

Learn more about how to submit using this pathway.

society members

Society Members

For your free access to this journal, log in via the IDSA members area.

Email Alerts

Register for email alerts and get notified as soon a new issue of Clinical Infectious Diseases is published online. And, with the IDSA Journals app, it's easy to stay connected, giving you the freedom to read the journal both online and offline, on your iPad, iPhone, or iPod Touch.

Sign up for alerts

IDSA Journals Now on X

X users can now follow all three IDSA journals to stay up to date and comment on the latest published articles, journal-related news, and announcements on special features and supplements.

Follow @CIDJournal 
Follow @JIDJournal
Follow @OFID Journal

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close